Review of antipsychotics in children and adolescents

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 14, 2006, Pages 1871-1885

  Kapetanovic, Suad ^a   Simpson, George M ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Antipsychotics; Aripiprazole; Chlorpromazine; Clozapine; Extrapyramidal side effects; Haloperidol; Neuroleptics; Olanzapine; Pimozide; Quetiapine; Risperidone; Thioridazine; Ziprasidone; Zuclopenthixol

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CENTRAL STIMULANT AGENT; CLONIDINE; CLOZAPINE; HALOPERIDOL; LITHIUM SALT; NEUROLEPTIC AGENT; NICOTINE PATCH; NORCLOZAPINE; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; PIMOZIDE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; VALPROATE SEMISODIUM; VALPROIC ACID; ZIPRASIDONE; ZUCLOPENTHIXOL;

ACADEMIC FAILURE; ADOLESCENT; AMENORRHEA; ANXIETY DISORDER; AREA UNDER THE CURVE; ASPERGER SYNDROME; ATTENTION DEFICIT DISORDER; AUTISM; BEHAVIOR MODIFICATION; BEHAVIOR THERAPY; BEHAVIORAL RESEARCH; BODY WEIGHT DISORDER; CHILD; CHILD BEHAVIOR; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COGNITIVE DEFECT; COGNITIVE THERAPY; COMORBIDITY; CONDUCT DISORDER; DEPRESSION; DEVELOPMENTAL DISORDER; DISEASE SEVERITY; DISRUPTIVE BEHAVIOR; DRUG ABSORPTION; DRUG CLEARANCE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG POTENTIATION; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GALACTORRHEA; GILLES DE LA TOURETTE SYNDROME; HIGH RISK PATIENT; HUMAN; HYPERPROLACTINEMIA; INTELLIGENCE QUOTIENT; MAJOR DEPRESSION; MANIA; MENTAL DEFICIENCY; MENTAL DISEASE; METABOLIC SYNDROME X; MIXED MANIA AND DEPRESSION; MOOD DISORDER; NARCOLEPSY; NEUTROPENIA; NONALCOHOLIC FATTY LIVER; PSYCHOLOGICAL RATING SCALE; PSYCHOSIS; QT INTERVAL; RECURRENT DISEASE; REMISSION; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; SEDATION; SEIZURE; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SUICIDAL BEHAVIOR; TACHYCARDIA; TIC; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT GAIN;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CENTRAL NERVOUS SYSTEM DISEASES; CHILD; CHILD, PRESCHOOL; EXPERT TESTIMONY; FEMALE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS;

EID: 33749343278     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.14.1871     Document Type: Review

References (94)

1. OLFSON M, BLANCO C, LIU L, MORENO C, LAJE G: National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch. Gen. Psychiatry (2006) 63(6):679-685.
2. PATEL NC, CRISMON ML, HOAGWOOD K et al: Trends in the use of typical and atypical antipsychotics in children and adolescents. J. Am. Acad. Child Adolesc. Psychiatry (2005) 44(6):548-556.
3. SCHUR SB, SIKICH I, FINDLING RL et al.: Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY), part I: a review. J. Am. Acad. Child Adolesc. Psychiatry (2003) 42:132-144.
4. PATEL NC, CRISMON ML, HOAGWOOD K, JENSEN PS: Unanswered questions regarding atypical antipsychotic use in aggressive children and adolescents. J. Child Adolesc. Psychopharmacology (2005) 15(2):270-284.
5. PAPPADOPULOUS E, MACINTYRE JC, CRISOM ML et al.: Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY), part II: J. Am. Acad. Child Adolesc. Psychiatry (2003) 42(2):145-161.
6. AACAP OFFICIAL ACTION: Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. J. Am. Acad. Child Adolesc. Psychiatry (2001) 41(7 Supplement): 4S-23S.
7. FINDLING RL, STEINER H, WELLER EB: Use of antipsychotics in children and adolescents. J. Clin. Psychiatry (2005) 66(Suppl 7):29-40.
8. CAMPBELL M, RAPOPORT JL, SIMPSON GM: Antipsychotics in children and adolescents. J. Am. Acad. Child Adolesc. Psychiatry (1999) 38(5):537-545.
9. ZALZMAN G, CARMON E, MARTIN A, BENSASON D, WEIZMAN A, TYANO S: Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study. J. Child Adolesc. Psychopharmacol. (2003) 13(3):319-327.
10. ARMENTEROS JL, WHITAKER AH, WELIKSON M, STEDGE DJ, GORMAN J: Risperidone in adolescents with schizophrenia: an open pilot study. J. Am. Acad. Child Adolesc. Psychiatry (1997) 36(5):694-700.
11. KUMRA S, JACOBSEN LK, LENANE M et al: Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents. J. Am. Acad. Child Adolesc. Psychiatry (1998) 37(4):377-385.
12. FINDLING RL, MCNAMARA NK, YOUNGSTROM EA, BRANICKY LA, DEMETER CA, SCHULZ SC: A prospective, open-label trial of olanzapine in adolescents with schizophrenia. J. Am. Acad. Child Adolesc. Psychiatry (2003) 42(2):170-175.
13. SHOLEVAR EH, BARON DA, HARDIE TL: Treatment of childhood-onset schizophrenia with olanzapine. J. Child. Adolesc. Psychopharmacol. (2000) 10(2):69-78.
14. SIKICH L, HAMER RM, BASHFORD RA, SHEITMAN BB, LIEBERMAN JA: A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology (2004) 29(1):133-145.
15. KUMRA S, FRAZIER JA, JACOBSEN LK et al.: Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison. Arch. Gen. Psychiatry (1996) 53(12):1090-1097.
16. SHAW P, SPORN A, GOGTAY N et al.: Childhood-onset schizophrenia. A double-blind, randomized clozapine-olanzapine comparison. Arch. Gen. Psychiatry (2006) 63(7):721-730.
17. SALLEE FR, DOUGHERTY D, SETHURAMAN G, VRINDAVANAM N: Prolactin monitoring of haloperidol and pimozide treatment in children with Tourette's syndrome. Biol. Psychiatry (1996) 40(10):1044-1050.
18. SALLEE FR, NESBITT L, JACKSON C, SINE L, SETHURAMAN G: Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder. Am. J. Psychiatry (1997) 154(8):1057-1062.
19. SCAHILLL L, LECKMAN JF, SCHULTZ RT, KATSOVICH L, PETERSON BS: A placebo-controlled trial of risperidone in Tourette syndrome. Neurology (2003) 60(7):1130-1135.
20. SALLEE FR, KURLAN R, GOETZ CG et al.: Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study. J. Am. Acad. Child. Adolesc. Psychiatry. (2000) 39(3):292-299.
21. GAFFNEY GR, PERRY PJ, LUND BC, BEVER-STILLE KA, ARNDT S, KUPERMAN S: Risperidone versus clonidine in the treatment of children and adolescents with Tourette's syndrome. J. Am. Acad. Child Adolesc. Psychiatry (2002) 41(3):330-336.
22. BRUGGEMAN R, VAN DER LINDEN C, BUITELAAR JK, GERICKE GS, HAWKRIDGE SM, TEMLETT JA: Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study. J. Clin. Psychiatry (2001) 62(1):50-56.
23. GILBERT DL, BATTERSON JR, SETHURAMAN G, SALLEE FR: Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial. J. Am. Acad. Child Adolesc. Psychiatry (2004) 43(2):206-214.
24. STEPHENS RJ, BASSEL C, SANDOR P: Olanzapine in the treatment of aggression and tics in children with Tourette's syndrome - a pilot study. J. Child Adolesc. Psychopharmacol. (2004) 14(2):255-266.
25. MUKADDES NM, ABALI O: Quetiapine treatment of children and adolescents with Tourette'sdisorder. J. Child Adolesc. Psychopharmacol. (2003) 13(3):295-299.
26. SNYDER R, TURGAY A, AMAN M et al.: Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J. Am. Acad. Child Adolesc. Psychiatry (2002) 41(9):1026-1036.
27. AMAN MG, DE SMEDT G, DERIVAN A, LYONS B, FINDLING RL: Risperidone Disruptive Behavior Study Group. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am. J. Psychiatry (2002) 159(8):1337-1346.
28. AMAN MG, BINDER C, TURGAY A: Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. J. Child Adolesc. Psychopharmacol. (2004) 14(2):243-254.
29. LEBLANC JC, BINDER CE, ARMENTEROS JL et al.: reduces aggression in boys with a disruptive behaviour disorder and below average intelligence quotient: analysis of two placebo-controlled randomized trials. Int. Clin. Psychopharmacol. (2005) 20(5):275-283.
30. VAN BELLINGHEN M, DE TROCH C: Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial. J. Child Adolesc. Psychopharmacol. (2001) 11(1):5-13.
31. SPIVAK B, MOZES T, MESTER R, KODLEIK M, WEIZMAN A: Zuclopenthixol treatment of behavioral disturbances in mentally retarded children and adolescents: an open-label study. J. Child Adolesc. Psychopharmacol. (2001) 11(3):279-284.
32. HANDEN BL, HARDAN AY: Open-label, prospective trial of olanzapine in adolescents with subaverage intelligence and disruptive behavior disorders. J. Am. Acad. Child Adolesc. Psychiatry (2006) 45(8):928-935.
33. MALONE RP, CATER J, SHEIKH RM, CHOUDHURY MS, DELANEY MA: Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J. Am. Acad. Child Adolesc. Psychiatry (2001) 40(8):887-894.
34. POTENZA MN, HOLMES JP, KANES SJ, MCDOUGLE CJ: Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J. Clin. Psychopharmacol. (1999) 19(1):37-44.
35. MASI G, COSENZA A, MUCCI M, BROVEDANI P: Open trial of risperidone in 24 young children with pervasive developmental disorders. J. Am. Acad. Child Adolesc. Psychiatry (2001) 40(10):1206-1214.
36. NICOLSON R, AWAD G, SLOMAN L: An open trial of risperidone in young autistic children. J. Am. Acad. Child Adolesc. Psychiatry (1998) 37(4):372-376.
37. MCDOUGLE CJ, HOLMES JP, BRONSON MR et al.: Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. J. Am. Acad. Child Adolesc. Psychiatry (1997) 36(5):685-693.
38. FINDLING RL, MAXWELL K, WIZNITZER M: An open clinical trial of risperidone monotherapy in young children with autistic disorder. Psychopharmacol. Bull. (1997) 33(1):155-159.
39. MCCRACKEN JT, MCGOUGH J, SHAH B et al.: Risperidone in children with autism and serious behavioral problems. N. Engl. J. Med. (2002) 347(5):314-321.
40. SHEA S, TURGAY A, CARROLL et al.: Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics (2004) 114:634-641.
41. RAUSCH JL, SIROTA EL, LONDINO DL et al.: Open-label risperidone for Asperger's disorder: negative symptom spectrum response. J. Clin. Psychiatry (2005) 66(12):1592-1597.
42. FINDLING RL, MCNAMARA NK, BRANICKY LA, SCHLUCHTER MD, LEMON E, BLUMER JL: A double-blind pilot study of risperidone in the treatment of conduct disorder. J. Am. Acad. Child Adolesc. Psychiatry (2000) 39(4):509-516.
43. DELBELLO MP, SCHWIERS ML, ROSENBERG HL, STRAKOWSKI SM: A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J. Am. Acad. Child Adolesc. Psychiatry (2002) 41(10):1216-1223.
44. DELBELLO MP, KOWATCH RA, ADLER CM et al.: A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. J. Am. Acad. Child Adolesc. Psychiatry (2006) 45(3):305-313.
45. BIEDERMAN J, MICK E, HAMMERNESS P et al.: Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children. Biol. Psychiatry (2005) 58(7):589-594.
46. BIEDERMAN J, MICK E, WOZNIAK J, ALEARDI M, SPENCER T, FARAONE SV: An open-label trial of risperidone in children and adolescents with bipolar disorder. J. Child Adolesc. Psychopharmacol (2005) 15(2):311-317.
47. FRAZIER JA, BIEDERMAN J, TOHEN M et al.: A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. J. Child Adolesc. Psychopharmacol. (2001) 11(3):239-250.
48. KAFANTARIS V, DICKER R, COLETTI DJ, KANE JM: Adjunctive antipsychotic treatment is necessary for adolescents with psychotic mania. J. Child Adolesc. Psychopharmacol. (2001) 11(4):409-413.
49. MOZES T, GREENBERG Y, SPIVAK B, TYANO S, WEIZMAN A, MESTER R: Olanzapine treatment in chronic drug-resistant childhood-onset schizophrenia: an open-label study. J. Child Adolesc. Psychopharmacol. (2003) 13(3):311-317.
50. ROSS RG, NOVINS D, FARLEY GK, ADLER LE: A 1-year open-label trial of olanzapine in school-age children with schizophrenia. J. Child Adolesc. Psychopharmacol. (2003) 13(3):301-309.
51. MCGLASHAN TH, ZIPURSKY BD, PERKINS D et al.: Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am. J. Psychiatry (2006) 163:790-799.
52. KRANZLER H, ROOFEH D, GERBINO-ROSEN G et al.: Clozapine: its impact on aggressive behavior among children and adolescents with schizophrenia. J. Am. Acad. Child Adolesc. Psychiatry (2005) 44(1):55-63.
53. MCGORRY PD, YUNG AR, PHILLIPS LJ et al.: Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch. Gen. Psychiatry (2002) 59(10):921-928.
54. TOURETTE SYDROME STUDY GROUP: Short-term versus longer term pimozide therapy in Tourette's syndrome: a preliminary study. Neurology (1999) 52(4):874-877.
55. SILVER AA, SHYTLE RD, PHILIPP MK, SANBERG PR: Case study: long-term potentiation of neuroleptics with transdermal nicotine in Tourette's syndrome. J. Am. Acad. Child Adolesc. Psychiatry (1996) 35(12):1631-1636.
56. GAGLIANO A, GERMANO E, PUSTORINO G et al.: Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications. J. Child Adolesc. Psychopharmacol. (2004) 14(1):39-47.
57. MALONE RP, MAISLIN G, CHOUDHURY MS, GIFFORD C, DELANEY MA: Risperidone treatment in children and adolescents with autism: short-and long-term safety and effectiveness. J. Am. Acad. Child Adolesc. Psychiatry (2002) 41(2):140-147.
58. ZUDDAS A, DI MARTINO A, MUGLIA P, CIANCHETTI C: Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation. J. Child. Adolesc. Psychopharmacol. (2000) 10(2):79-90.
59. TROOST PW, LAHUIS BE, STEENHUIS MP et al.: Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. J. Am. Acad. Child Adolesc. Psychiatry (2005) 44(11):1137-1144.
60. RESEARCH UNITS ON PEDIATRIC PSYHCOPHAMACOLOGY AUTISM NETWORK: Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. Am. J. Psychiatry (2005) 162(7):1361-1369.
61. MCDOUGLE CJ, SCAHILL L, AMAN MG et al.: Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on paediatric psychopharmacology. Am. J. Psychiatry (2005) 162(6):1142-1148.
62. WILLIAMS SK, SCAHILL L, VITIELLO B et al.: Risperidone and adaptive behavior in children with autism. J. Am. Acad. Child Adolesc. Psychiatry (2006) 45(4):431-439.
63. ZUDDAS A, LEDDA MG, FRATTA A, MUGLIA P, CIANCHETTI C: Clinical effects of clozapine on autistic disorder. Am. J. Psychiatry (1996) 153(5):738.
64. CROONENBERGHS J, FEGERT JM, FINDLING RL et al.: Risperidone in children with disruptive behavior disorders and subaverage intelligence: a 1-year, open-label study of 504 patients. J. Am. Acad. Child Adolesc. Psychiatry (2005) 44(1):64-72.
65. FINDLING RL, AMAN MG, EERDEKENS M et al.: Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. Am. J. Psychiatry (2004) 161(4):677-684.
66. TURGAY A, BINDER C, SNYDER R, FISMAN S: Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics (2002) 110(3):e34.
67. HARDAN A, JOHNSON K, JOHNSON C, HRECZNYJ B: Case study: risperidone treatment of children and adolescents with developmental disorders. J. Am. Acad. Child Adolesc. Psychiatry (1996) 35(11):1551-1556.
68. REYES M, CROONENBERGHS J, AUGUSTYNS I, EERDEKENS M: Long-term use of risperidone in children with disruptive behavior disorders and subaverage intelligence: efficacy, safety and tolerability. J. Child Adolesc. Psychopharmacol. (2006) 16(3):260-272.
69. ZARCONE JR, HELLINGS JA, CRANDALL K et al.: Effects of risperidone on aberrant behavior of persons with developmental disabilities: I. A double-blind crossover study using multiple measures. Am. J. Ment. Retard. (2001) 106(6):525-538.
70. REYES M, BUITELAAR J, TOREN P, AUGUSTYNS I, EERDEKENS M: A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am. J. Psychiatry (2006) 163(3):402-410.
71. PAVULURI MN, HENRY DB, CARBRAY JA, SAMPSON G, NAYLOR MW, JANICAK PG: Open-label prospective trial of risperidone in combination with lithium or divalproex sodium in pediatric mania. J. Affect. Disord. (2004) 82(Suppl. 1):S103-111.
72. CARLSON HE, CORELL CU: Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J. Am. Acad. Child Adolesc. Psychiatry (2006) 45(7):771-791.
73. FINDLING RL, KUSUMAKAR V, DANEMAN D, MOSHANG T, DE SMEDT G, BINDER C: Prolactin levels during long-term risperidone treatment in children and adolescents. J. Clin. Psychiatry (2003) 64(11):1362-1369.
74. SAITO E, CORRELL CU, GALLELLI K et al.: A prospective study of hyperprolactinemia in children and adolescents treated with atypical antipsychotic agents. J. Child Adolesc. Psychopharmacol. (2004) 14(3):350-358.
75. MCCONVILLE BJ, ARVANITIS LA, THYRUM PT et al.: Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders. J. Clin. Psychiatry (2000) 61(4):252-260.
76. STALLER J: The effect of long-term antipsychotic treatment on prolactin. J. Child Adolesc. Psychopharmacol. (2006) 16(3):317-326.
77. WUDARSKY M, NICOLSON R, HAMBURGER SD et al.: Elevated prolactin in paediatric patients on typical and atypical antipsychotics. J. Child Adolesc. Psychopharmacol. (1999) 9(4):239-245.
78. BUITELAAR JK: Open-label treatment with risperidone of 26 psychiatrically-hospitalized children and adolescents with mixed diagnoses and aggressive behavior. J. Child. Adolesc. Psychopharmacol. (2000) 10(1):19-26.
79. DESARKAR P, ANUPAM THAKUR T, SINHA VK: Aripiprazole-induced acute dystonia. Am. J. Psychiatry (2006) 163(6):1112-1113.
80. HELLINGS JA, ZARCONE JR, CRANDALL K, WALLACE D, SCHROEDER SR: Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. J. Child Adolesc. Psychopharmacol. (2001) 11(3):229-238.
81. MARTIN A, SCAHILL L, ANDERSON GM et al.: Weight and leptin changes among risperidone-treated youths with autism:6-month prospective data. Am. J. Psychiatry (2004) 161(6):1125-1227.
82. BLAIR J, SCAHILL L, STATE M, MARTIN A: Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study. J. Am. Acad. Child Adolesc. Psychiatry (2005) 44(1):73-79.
83. HOLTMANN M, KOPF D, MAYER M, BECHTINGER E, SCHMIDT MH: Risperidone-associated steatohepatitis and excessive weight-gain. Pharmacopsychiatry (2003) 36(5):206-207.
84. SPALDING S, ALESSI LE, RADWAN K: Aripiprazole and atypical neuroleptic malignant syndrome. J. Am. Acad. Child Adolesc. Psychiatry (2004) 43(12):1457-1458.
85. HAMMERMAN S, LAM C, CAROFF SN: Neuroleptic malignant syndrome and aripiprazole. J. Am. Acad. Child Adolesc. Psychiatry (2006) 45(6):639-641.
86. SALLEE FR, GILBERT DL, VINKS AA, MICELI JJ, ROBARGE L, WILNER K: Pharmacodynamics of ziprasidone in children and adolescents: impact on dopamine transmission. J. Am. Acad. Child Adolesc. Psychiatry. (2003) 42(8):902-907.
87. SALLEE FR, MICELI JJ, TENSFELDT T, ROBARGE L, WILNER K, PATEL NC: Single-dose pharmacokinetics and safety of ziprasidone in children and adolescents. J. Am. Acad. Child Adolesc. Psychiatry (2006) 45(6):720-728.
88. FRAZIER JA, COHEN LG, JACOBSEN L et al.: Clozapine pharmacokinetics in children and adolescents with childhood-onset schizophrenia. J. Clin. Psychopharmacol. (2003) 23(1):87-91.
89. GROTHE DR, CALIS KA, JACOBSEN L et al.: Olanzapine pharmacokinetics in paediatric and adolescent inpatients with childhood-onset schizophrenia. J. Clin. Psychopharmacol. (2000) 20(2):220-225.
90. THOMAS LE, WOODS SW: The schizophrenia prodrome: a developmentally informed review and update for psychopharmacologic treatment. Child Adolesc. Psychiatr. Clin. N. Am. (2006) 15(1):109-133.
91. KOWATCH RA, DELBELLO MP: Pediatric bipolar disorder: emerging diagnostic and treatment approaches. Child Adolesc. Psychiatr. Clin. N. Am. (2006) 15(1):73-108.
92. AACAP OFFICIAL ACTION: Practice parameter for the assessment and treatment of children, adolescents and adults with autism and other pervasive developmental disorders. J. Am. Acad. Child Adolesc. Psychiatry (1999) 38(12 Suppl.):32S-54S.
93. KING BH, BOSTIC JQ: An update on pharmacologic treatments for autism spectrum disorders. Child Adolesc. Psychiatr. Clin. N. Am. (2006) 15(1):161-175.
94. CORRELL CU: Metabolic side effects of second-generation antipsychotics in children and adolescents: a different story? J. Clin. Psychiatry (2005) 66(10):1331-1332.